Are We Entering an Age of Expensive Personalised Medicines?
Contributor:
Pharma IQ
Posted: 09/20/2011 12:00:00 AM EDT | 0
Posted: 09/20/2011 12:00:00 AM EDT | 0
|
Since the approval of Pfizer's lung cancer drug Xalkori by the United States Food and Drug Administration (FDA), headlines have been calling into question the future of personalised medicine – and the cost it will bring with it.
Pfizer's own figures suggest the drug will only be of benefit to between 6,500 and 11,000 patients in the United States who are suffering from AKL positive metastatic non-sma...
-
Translational Medicine 2020: What Does the Future Hold? -
Revolutionising Healthcare in Asia Through IT -
The SAT-EU Survey on Attitudes Towards Trial Site Selection in Europe -
Portuguese Hospitals Block Access to New Medicines as Retail Drug Sector Expected to Meet Savings Goal -
Opportunities and Challenges for New Chinese GMP Compliance -
Commercialisation of Regenerative Medicine -
Seven Steps To Considering Clinical Trials in Asia -
Waltzing Away in Pharma Wonderland with Polichinelle -
Emerging Markets Clinical Trials: Asia Harnessing the Best of the East and the West to Advance Clinical Development -
Can Social Media Play a Role in E-Discovery?
* = required.
Not a member yet? Sign up
You Should Check Out:
Events of Interest
-
Exploring Challenges and Opportunities in Predictive Safety Tools: Trends from Industry-Wide Surveys
January 13, 2012
Register Now -
Regenerative Medicine and Barriers to Commercialisation Online Summit 2011
October 25, 2011
Register Now -
Taking EDC to the next level: Moving from point solutions to an eClinical ecosystem
April 4, 2013
Register Now -
Global HTA and CER Forum 2011
August 31, 2011
Register Now




Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!